Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Well Corp (AMWL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Well Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while American Well Corp trades at $8.79 (market cap $150.21M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 29.9× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | AMWL | |
|---|---|---|
Market Cap | $4.49B | $150.21M |
Sector | Health | Health |
52-Week High | $28.06 | $9.83 |
52-Week Low | $20.06 | $3.78 |
Enterprise Value | $3.69B | -$25.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AMWL trades at $8.99, down 2.81% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving financial trends with revenue stabilizing near $249 million in 2025 and net losses narrowing to -$96 million. Recent news highlights momentum, including a Zacks upgrade to Buy on June 24, 2026, and Amazon appointing Amwell's co-founder to lead its healthcare unit on May 27, 2026.
Outlook remains cautious due to persistent losses and negative cash flow, though valuation metrics like P/S of 0.64 and P/B of 0.68 suggest potential upside if profitability improves. Risks include competitive pressures and execution challenges, but analyst consensus leans Hold with a $7.25 price target, indicating limited near-term growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
